Newest Treatment for Multiple Myeloma (2021)
Rafael Fonseca, MD
Dr. Rafael Fonseca has been a practicing hematologist for almost three decades, now interim executive director at Mayo Clinic.
As a veteran specialist of the myeloma field, he shares his insights on the latest in emerging treatments and clinical trial studies for this series focused on the newest treatment for multiple myeloma.
This introductory episode focuses on the landscape of front line or first line treatment for multiple myeloma, from induction therapy, the various go-to drugs and how they’re used, personalizing treatment, and the most commonly reported side effects.
Dr. Fonseca describes his typical treatment regimen for multiple myeloma patients who’ve become triple-class refractory. He dives deeper into drugs like selinexor, melflufen, and belantamab mafodotin, as well as commonly reported side effects and how to manage them.
Dr. Fonseca shares his insights on emerging T-cell therapies for multiple myeloma, describing the role T-cells play in our bodies and then focusing on chimeric antigen receptor (CAR) T-cell therapy and bispecific T-cell engagers (BiTEs).
In this episode, Dr. Fonseca details the process of clinical trials, as well as how patients and families can better understand what goes on during each of the main parts of the study.
Learn more about the newer class of drugs known as “CELMoDs,” the development of preventative vaccines for myeloma and who might benefit, and Dr. Fonseca’s last message for myeloma patients and caregivers.
- Name: Dr. Rafael Fonseca
- Interim director, Mayo Clinic Cancer Center
- Director, Innovation and Transformational Relationships at Mayo Clinic (Arizona)
- Experience: ~30 years
- Areas of Focus:
- Clinical trials for myeloma and related conditions
- Genetics of myeloma
- New drug development
- Approach with patients: Understanding & cognizant of difficulties diagnosis brings